These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11115604)

  • 1. Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)).
    Arranz MJ; Mancama D; Kerwin RW
    Int J Mol Med; 2001 Jan; 7(1):27-30. PubMed ID: 11115604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic strategies for the personalization of antipsychotic treatment.
    Kerwin RW; Mancama DT; Arranz MJ
    Expert Rev Mol Diagn; 2001 Sep; 1(3):275-80. PubMed ID: 11901832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
    Reynolds GP; Templeman LA; Zhang ZJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetics and tailored drug treatment in schizophrenia].
    Andreassen OA; Steen VM
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Receptor polymorphism and response to treatment in schizophrenia].
    Szekeres G; Janka Z
    Orv Hetil; 2002 Sep; 143(35):2027-33. PubMed ID: 12387196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
    Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
    Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment.
    Arranz MJ; Kerwin RW
    Ann Med; 2000 Mar; 32(2):128-33. PubMed ID: 10766404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomics and the future of pharmacotherapy in psychiatry.
    Malhotra AK; Lencz T; Correll CU; Kane JM
    Int Rev Psychiatry; 2007 Oct; 19(5):523-30. PubMed ID: 17896232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal fallacies of antipsychotic drugs.
    Erickson SK; Ciccone JR; Schwarzkopf SB; Lamberti JS; Vitacco MJ
    J Am Acad Psychiatry Law; 2007; 35(2):235-46. PubMed ID: 17592170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives.
    Gesteira A; Barros F; Martín A; Pérez V; Cortés A; Baiget M; Carracedo A
    Actas Esp Psiquiatr; 2010; 38(5):301-16. PubMed ID: 21117005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of antipsychotics: useful for the clinician?
    Bondy B; Spellmann I
    Curr Opin Psychiatry; 2007 Mar; 20(2):126-30. PubMed ID: 17278909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pharmacogenetics on the development and use of antipsychotic drugs.
    Reynolds GP
    Drug Discov Today; 2007 Nov; 12(21-22):953-9. PubMed ID: 17993414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.